

**ZOETIS INC.****333 PORTAGE STREET, KALAMAZOO, MI, 49007**

Telephone: 269-359-4414

Customer Service: 888-963-8471

Website: [www.zoetis.com](http://www.zoetis.com)

THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

**BOVI-SHIELD GOLD ONE SHOT®****Zoetis****Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza<sub>3</sub>-Respiratory Syncytial Virus Vaccine**

Modified Live Virus

**Mannheimia Haemolytica Toxoid**

This product has been shown to be effective for vaccination of healthy cattle against respiratory disease caused by infectious bovine rhinotracheitis (IBR) virus, parainfluenza<sub>3</sub> (PI<sub>3</sub>) virus, and bovine respiratory syncytial virus (BRSV); respiratory disease and viremia caused by bovine virus diarrhea (BVD) Type 1, including 1b, and Type 2 virus; and bovine pneumonia caused by *Mannheimia haemolytica* type A1. A duration of immunity of at least 9 months has been demonstrated against IBR and BVD Types 1 and 2 respiratory disease and viremia caused by BVD Types 1 and 2; and at least 9 weeks against *M. haemolytica*. Duration of immunity against the remaining fractions has not been established. For more information regarding efficacy and safety data, go to [productdata.aphis.usda.gov](http://productdata.aphis.usda.gov).

Onset of immunity against *M. haemolytica* has been demonstrated as early as 7 days after product administration.

Bovi-Shield GOLD One Shot may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP® or PregGuard® GOLD FP vaccine within the past 12 months. Bovi-Shield GOLD One Shot may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above. To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP or PregGuard GOLD FP product with the second dose administered approximately 30 days prebreeding.

**DIRECTIONS:**

*General Directions:* Vaccination of healthy cattle is recommended. Aseptically rehydrate the freeze-dried component with the sterile diluent provided, mix well, and administer 2 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered in the neck region.

*Primary Vaccination:* Administer a single 2-mL dose to healthy cattle. The presence of maternal antibody is known to interfere with the development of active immunity in cattle and additional boosters will be required in most young animals.

*Revaccination:* Historically, annual revaccination with this product was recommended. The need for booster vaccinations has not been established for this product; consultation with a veterinarian or the manufacturer is recommended.

Good management practices support revaccination whenever subsequent stress or exposure is likely.

**PRECAUTIONS:**

Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine within the past 12 months. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above.

To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP or PregGuard GOLD FP product with the second dose administered approximately 30 days prebreeding.

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

Inactivate unused contents before disposal.

Do not vaccinate within 21 days before slaughter.

Contains gentamicin as preservative.

Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Management strategies based on vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

Do not mix with other products, except as specified above.

In case of human exposure, contact a physician.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

For veterinary use only

VLN 190/PCN 4X41.20

Zoetis Inc., Kalamazoo, MI 49007, USA

50797001

**Presentation:** 5, 10 and 50 doses.

**CPN:** 3690366.1